Last reviewed · How we verify
Dextrose 5% in water (D5W)
Dextrose 5% in water provides a source of glucose and free water for intravenous hydration and caloric supplementation.
Dextrose 5% in water provides a source of glucose and free water for intravenous hydration and caloric supplementation. Used for Intravenous hydration and maintenance fluid therapy, Caloric supplementation in hospitalized patients, Prevention and treatment of dehydration.
At a glance
| Generic name | Dextrose 5% in water (D5W) |
|---|---|
| Also known as | Placebo |
| Sponsor | Hospital for Special Surgery, New York |
| Drug class | Intravenous fluid / Crystalloid solution |
| Modality | Small molecule |
| Therapeutic area | Supportive care / Fluid and electrolyte management |
| Phase | FDA-approved |
Mechanism of action
D5W is a hypotonic crystalloid solution that delivers dextrose (glucose) and water intravenously. The dextrose is metabolized for energy and the water distributes across intracellular and extracellular compartments, providing both modest caloric support and free water for rehydration. It is commonly used for maintenance fluid therapy and to prevent dehydration in hospitalized patients.
Approved indications
- Intravenous hydration and maintenance fluid therapy
- Caloric supplementation in hospitalized patients
- Prevention and treatment of dehydration
Common side effects
- Hyperglycemia
- Hyponatremia (with prolonged use)
- Phlebitis at infusion site
- Fluid overload
Key clinical trials
- The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (PHASE4)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Impact of Bupivacaine Dilution With Dextrose or Saline on Infraclavicular Block Outcomes (NA)
- Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke (PHASE2)
- Cervical Plexus Hydrodissection With D5W Versus NS for Treatment-Resistant PTSD (PHASE4)
- Ceftriaxone for Post-Treatment Lyme Disease (PHASE1, PHASE2)
- Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... (PHASE2)
- Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextrose 5% in water (D5W) CI brief — competitive landscape report
- Dextrose 5% in water (D5W) updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI